

Press Release

Kiwoom Asset Management Launches ETF Tracking Solactive Blockbuster Biotech Drugs Index

28 May 2024

FRANKFURT AM MAIN – Solactive is proud to partner with South Korea's Kiwoom Asset Management on the launch of the KIWOOM KOSEF US Blockbuster Biotech Drugs Plus ETF, which tracks the performance of the Solactive Blockbuster Biotech Drugs Index.

The biopharma sector has undergone disruptive growth, primarily driven by data-powered insights and increasingly sophisticated medical technology, leading to soaring investments and activities in areas such as early detection and curative therapies, with over US\$8.9 billion investments in cell and gene therapies in 2019 and this number is ever-growing.¹ According to industry reports, the biopharmaceuticals industry is expected to experience an annual sales growth of 5.2% until 2028, where extensive research on various acute and even chronic diseases continues to accelerate the development of groundbreaking drugs and treatments, creating a compelling investment opportunity.²

The **Solactive Blockbuster Biotech Drugs Index (SOLBBBD)** aims to capture the performance of companies operating in the biotech industry, with focus on the so-called **Blockbuster Drug** companies. These companies have achieved annual biotechnology product revenues of more than \$1 billion with at least one product. Additionally, an Expected Biotech Blockbuster Company will also be considered for index inclusion, with at least one product that is expected to generate revenues exceeding \$1 billion over the 5-year period following the selection day. The index constituents are weighted according to the Biotech Blockbuster Drug revenues over a 5-year period, with an upper cap at 10%.

The ETF listed on 28 May 2024 on the Korea Stock Exchange (KRX) with the ticker code 483030.KS.

Timo Pfeiffer, Chief Markets Officer at Solactive, comments: "In a post-COVID world, the biotech sector is no longer reserved for niche experts but has captured the attention of the broader public. We believe that this

¹<https://www2.deloitte.com/cn/en/pages/life-sciences-and-healthcare/articles/the-future-of-biopharma.html>

²<https://www.morningstar.com/lp/biopharma-landscape>

Solactive AG
German Index Engineering
Platz der Einheit 1
60327 Frankfurt am Main
Germany

Steffen Scheuble
CEO
+49 (69) 719 160-20
steffen.scheuble@solactive.com

Michael Li Ming Nuske, CFA
Team Head Sales APAC
+852 3905 3101
michael.nuske@solactive.com

Maria Seifert/Gabriela Ormazabal
PR & Communications
+49 (69) 719 160-311
press@solactive.com

index strategically enhances access to a vital industry like biopharmaceuticals that continues to shape the future of human health. On this note, we are very pleased to continue our partnership with Kiwoom and take great pride in launching the Solactive Blockbuster Biotech Drugs Index with our ongoing commitment to pioneering and forward-thinking endeavors in the indexing space."

Seongin Jeong, Head of ETF Business Department at Kiwoom, comments: " *We are very pleased to collaborate with Solactive, which has a strong track record in developing strategic indexes, to launch a new product that provides strategic exposure to the biotechnology industry, which is expected to grow in the future.*

The presence of blockbuster drugs in a biotech company and the size of blockbuster drug sales are useful indicators of the size and sustainability of a company's revenue.

KIWOOM KOSEF US Blockbuster Biotech Drugs Plus ETF, which invests in companies on a blockbuster drug revenue-weighted basis, will provide global investors with an effective way to invest in blue-chip biotech companies with proven innovation and profitability."

For more information, please visit:

<http://www.solactive.com>

Note to editors

About Solactive

Solactive is a leading provider of indexing, benchmarking, and calculation solutions for the global investment and trading community. Headquartered in Frankfurt and, with offices in Hong Kong, Toronto, Berlin, Dresden, and Amsterdam, we innovate and disrupt the status quo as the partner of choice for our clients.

The unique blend of our 300 staff's expertise in data, data science, financial markets, and technology enables our clients' continued success through the delivery of a superior experience, unique customization capabilities, and the best value for money available in the industry. With more than 26,000 indices calculated daily, we offer a full suite of solutions, including market-leading ESG and thematic indices.

Solactive AG
German Index Engineering
Platz der Einheit 1
60327 Frankfurt am Main
Germany

Steffen Scheuble
CEO
+49 (69) 719 160-20
steffen.scheuble@solactive.com

Michael Li Ming Nuske, CFA
Team Head Sales APAC
+852 3905 3101
michael.nuske@solactive.com

Maria Seifert/Gabriela Ormazabal
PR & Communications
+49 (69) 719 160-311
press@solactive.com

As at January 2024, Solactive served approximately 500 clients across the world, with approximately US\$300 billion invested in products linked to our indices. Solactive is registered with ESMA as a benchmark administrator and is supervised by the BaFin.

Disclaimer

The information in this document does not constitute tax, legal or investment advice and is not intended as a recommendation for buying or selling securities. Solactive AG and all other companies mentioned in this document are not responsible for the consequences of reliance upon any opinion or statement contained herein or for any omission.

Solactive AG, Platz der Einheit 1, 60327 Frankfurt am Main, Germany. Registered Office: Frankfurt am Main, Registration Court: Amtsgericht Frankfurt am Main, HRB: 79986, USt-IdNr.: DE 255 598 976. Management Board: Steffen Scheuble, Alexander Steiner, and Timo Pfeiffer, Head of Supervisory Board: Dr Felix Mühlhäuser.

Solactive AG
German Index Engineering
Platz der Einheit 1
60327 Frankfurt am Main
Germany

Steffen Scheuble
CEO
+49 (69) 719 160-20
steffen.scheuble@solactive.com

Michael Li Ming Nuske, CFA
Team Head Sales APAC
+852 3905 3101
michael.nuske@solactive.com

Maria Seifert/Gabriela Ormazabal
PR & Communications
+49 (69) 719 160-311
press@solactive.com